Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
5960.5000 -187.50 (-3.05%)
NSE May 08, 2025 15:31 PM
Volume: 364.9K
 

5960.50
-3.05%
Motilal Oswal
concerns. However, EBITDA margin at 34.9% (our estimate: 39.6%) was marginally down by 60bp YoY compared to the fall in GM. This is due to lower other expenses (excluding one-offs), down 130bp YoY, and employee cost, down 60bp YoY (as % of sales). Other expenses had one-offs due to 1) Forex loss of INR74m and 2) Considerably higher amount of INR300m towards CSR. EBITDA at INR4.3b (our est. INR5.2b) grew 13% YoY. Adj. PAT at INR3b (our est. INR4b) grew at higher rate of 25% YoY due to lower tax rate for the quarter. For FY19, Sales/EBITDA/PAT at INR49b/INR19b/INR13b grew 26%/48%/55% on YoY basis....
Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.
More from Divi's Laboratories Ltd.
Recommended